{
    "clinical_study": {
        "@rank": "70479", 
        "arm_group": {
            "arm_group_label": "BeGEV", 
            "arm_group_type": "Experimental", 
            "description": "Bendamustine, Gemcitabine and Vinorelbine (BeGEV)"
        }, 
        "brief_summary": {
            "textblock": "Test of bendamustine in combination with gemcitabine and vinorelbine could contribute to a\n      higher response rate with the reduction of toxic side effects"
        }, 
        "brief_title": "Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Hodgkin's Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Hodgkin Disease", 
                "Lymphoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "The aim of this study is to evaluate bendamustine, gemcitabine and vinorelbine (BeGEV)\n      scheme efficacy as induction therapy to high dose chemotherapy with Allogeneic Hematopoietic\n      Stem-Cell Transplantation (AHSCT) for patients with relapsed/refractory Hodglin's Lymphoma\n      (HL).\n\n      Four BeGEV courses repeated every 3 weeks in the absence of any reasons listed in the\n      paragraph 7.5; whenever an objective response is observed at disease evaluation performed\n      after IV cycle patients undergo to high dose chemotherapy with AHSCT (conditioning regimens\n      based on preference of each Centre)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  relapsed/refractory disease after receiving one line of standard chemotherapy\n\n          -  history of classical Hodgkin's Lymphoma (HL)\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of \u2264 2\n\n          -  at least one site of measurable nodal disease at baseline \u2265 1.5 cm\n\n          -  Absolute Neutrophils Count (ANC) \u2265 1.5 x 109/L; Platelets count \u2265 75 x 109/L\n\n        Exclusion Criteria:\n\n          -  Diagnosis of Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL)\n\n          -  prior radiation therapy \u2264 3 weeks prior to start of study treatment\n\n          -  any concurrent anti-cancer therapy\n\n          -  evidence of another malignancy not in remission or history of such a malignancy\n             within the last 2 years.\n\n          -  aspartate aminotransferase (AST/SGOT) and/or alanine aminotransferase (ALT/SGPT) \u2265\n             2.5 x upper limit of normal (ULN) or \u2265 5.0 x ULN if the transaminase elevation is due\n             to disease involvement\n\n          -  known history of Human immunodeficiency virus (HIV)seropositivity\n\n          -  hepatitis B virus (HBV) or hepatitis B virus (HCV)active hepatitis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "59", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01884441", 
            "org_study_id": "ONC-2010-002", 
            "secondary_id": "2010-022169-91"
        }, 
        "intervention": [
            {
                "arm_group_label": "BeGEV", 
                "description": "Schedule:\nDay 2: Bendamustine 90mg/mq Day 3: Bendamustine 90mg/mq for a maximum of 4 cycles", 
                "intervention_name": "Bendamustine", 
                "intervention_type": "Drug", 
                "other_name": "Ribomustin"
            }, 
            {
                "arm_group_label": "BeGEV", 
                "description": "Day 1: Gemcitabine 800mg/mq, Day 4: Gemcitabine 800mg/mq for a maximum of 4 cycles", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug", 
                "other_name": "Gemzar"
            }, 
            {
                "arm_group_label": "BeGEV", 
                "description": "Day 1 Vinorelbine 20mg/mq for a maximum of 4 cycles", 
                "intervention_name": "Vinorelbine", 
                "intervention_type": "Drug", 
                "other_name": "Navelbine"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Bendamustine", 
                "Vinorelbine", 
                "Nitrogen Mustard Compounds", 
                "Vinblastine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hodgkin", 
            "Lymphoma", 
            "refractory", 
            "relapsed"
        ], 
        "lastchanged_date": "January 28, 2014", 
        "location": {
            "contact": {
                "email": "armando.santoro@humanitas.it", 
                "last_name": "Armando Santoro, MD", 
                "phone": "+39 (0)2 8224", 
                "phone_ext": "4080"
            }, 
            "contact_backup": {
                "email": "rita.mazza@humanitas.it", 
                "last_name": "Rita Mazza, MD", 
                "phone": "+39 (0)2 8224", 
                "phone_ext": "4780"
            }, 
            "facility": {
                "address": {
                    "city": "Rozzano", 
                    "country": "Italy", 
                    "state": "MI", 
                    "zip": "20089"
                }, 
                "name": "Istituto Clinico Humanitas"
            }, 
            "investigator": [
                {
                    "last_name": "Armando Santoro, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Rita Mazza, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study With Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients Before High Dose Chemotherapy With Autologous Hematopoietic Stem Cells Transplant", 
        "overall_contact": {
            "email": "armando.santoro@humanitas.it", 
            "last_name": "Armando Santoro, MD", 
            "phone": "+39 (0)2 8224", 
            "phone_ext": "4080"
        }, 
        "overall_contact_backup": {
            "email": "rita.mazza@humanitas.it", 
            "last_name": "Rita Mazza, MD", 
            "phone": "+39 (0)2 8224", 
            "phone_ext": "4780"
        }, 
        "overall_official": {
            "affiliation": "Istituto Clinico Humanitas", 
            "last_name": "Armando Santoro, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "response rate after BeGEV in terms of Complete Response (CR)evaluated by fludeoxyglucose Positron emission tomography (FDG-PET) and Computed Tomography (CT-scan) after four cycles.", 
            "measure": "Response Rate", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01884441"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Istituto Clinico Humanitas", 
            "investigator_full_name": "Armando Santoro, MD", 
            "investigator_title": "MD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To assess the response rate after BeGEV in terms of overall response rate (ORR) =Complete Response (CR) plus Partial Response (PR)).", 
                "measure": "overall response rate", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "To evaluate the mobilization potential of BeGEV.", 
                "measure": "mobilization potential of the combination", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "To evaluate the toxicity of BeGEV in terms of haematological and extra-haematological side effects according to CTCAE definitions v 3.0.", 
                "measure": "toxicity of the combination", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Progression free survival and overall survival", 
                "measure": "Progression free survival (PFS), Overall Survival (OS).", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Istituto Clinico Humanitas", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Armando Santoro, MD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}